Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$131.25
0.980.75%
al cierre: -
$131.25
0.000.00%
After hour: 4:05 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Abbott Laboratories ha un obiettivo di prezzo di consenso pari a $139.6, stabilito in base alle ultime valutazioni degli analisti di 26. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, Raymond James y Mizuho il julio 18, 2025. Con un obiettivo di prezzo medio di $139.33 tra le Wells Fargo, Raymond James y Mizuho, c'è un implicito 6.16% upside per Abbott Laboratories da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
Raymond James
Mizuho
Jefferies
BTIG
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Abbott Laboratories
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/18/2025 | 8.19% | Wells Fargo | $147 → $142 | Maintains | Overweight | |||
07/18/2025 | 7.43% | Raymond James | $142 → $141 | Maintains | Outperform | |||
07/18/2025 | 2.86% | Mizuho | $140 → $135 | Maintains | Neutral | |||
07/18/2025 | 10.48% | Jefferies | $143 → $145 | Upgrade | Hold → Buy | |||
07/18/2025 | 10.48% | BTIG | $148 → $145 | Maintains | Buy | |||
07/16/2025 | 6.67% | Mizuho | $130 → $140 | Maintains | Neutral | |||
07/15/2025 | 12% | RBC Capital | $145 → $147 | Maintains | Outperform | |||
07/15/2025 | 4.38% | Morgan Stanley | $127 → $137 | Maintains | Equal-Weight | |||
07/08/2025 | 10.48% | Evercore ISI Group | $140 → $145 | Maintains | Outperform | |||
04/17/2025 | 8.19% | Raymond James | $132 → $142 | Maintains | Outperform | |||
04/17/2025 | 10.48% | Piper Sandler | $133 → $145 | Reiterates | Overweight → Overweight | |||
04/17/2025 | 10.48% | RBC Capital | $140 → $145 | Maintains | Outperform | |||
04/17/2025 | 12% | Wells Fargo | $136 → $147 | Maintains | Overweight | |||
04/17/2025 | -3.24% | Morgan Stanley | $117 → $127 | Maintains | Equal-Weight | |||
04/17/2025 | 21.14% | Barclays | $158 → $159 | Maintains | Overweight | |||
04/17/2025 | 10.48% | Stifel | $135 → $145 | Maintains | Buy | |||
04/17/2025 | 4.38% | Jefferies | $135 → $137 | Maintains | Hold | |||
03/10/2025 | 14.29% | B of A Securities | $133 → $150 | Maintains | Buy | |||
03/04/2025 | 21.9% | Citigroup | $135 → $160 | Maintains | Buy | |||
03/04/2025 | 17.33% | Goldman Sachs | $138 → $154 | Maintains | Buy | |||
01/27/2025 | 20.38% | Barclays | $149 → $158 | Maintains | Overweight | |||
01/23/2025 | 2.86% | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
01/23/2025 | 3.62% | Wells Fargo | $133 → $136 | Maintains | Overweight | |||
01/23/2025 | 2.86% | Stifel | $130 → $135 | Maintains | Buy | |||
01/23/2025 | 12.76% | UBS | $146 → $148 | Maintains | Buy | |||
01/21/2025 | 2.86% | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
11/05/2024 | 13.52% | Barclays | $143 → $149 | Maintains | Overweight | |||
10/17/2024 | 5.14% | Bernstein | $133 → $138 | Maintains | Outperform | |||
10/17/2024 | 11.24% | UBS | $143 → $146 | Maintains | Buy | |||
10/17/2024 | -4.76% | Jefferies | $120 → $125 | Maintains | Hold | |||
10/17/2024 | -0.95% | Mizuho | $115 → $130 | Maintains | Neutral | |||
10/17/2024 | 1.33% | Piper Sandler | $131 → $133 | Maintains | Overweight | |||
10/17/2024 | -10.86% | Morgan Stanley | $107 → $117 | Maintains | Equal-Weight | |||
10/14/2024 | -1.71% | Raymond James | $122 → $129 | Maintains | Outperform | |||
10/08/2024 | -0.95% | RBC Capital | $125 → $130 | Maintains | Outperform | |||
10/08/2024 | -0.95% | Oppenheimer | → $130 | Initiates | → Outperform | |||
10/01/2024 | -5.52% | Evercore ISI Group | $120 → $124 | Maintains | Outperform | |||
09/26/2024 | -8.57% | Jefferies | $120 → $120 | Reiterates | Hold → Hold | |||
09/19/2024 | -0.19% | Piper Sandler | → $131 | Initiates | → Overweight | |||
08/27/2024 | -8.57% | Jefferies | $112 → $120 | Maintains | Buy | |||
08/22/2024 | -3.24% | Citigroup | $119 → $127 | Maintains | Buy | |||
07/29/2024 | 8.95% | Barclays | $140 → $143 | Maintains | Overweight | |||
07/02/2024 | -8.57% | Evercore ISI Group | $125 → $120 | Maintains | Outperform | |||
06/04/2024 | -4.76% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
05/30/2024 | -7.81% | Goldman Sachs | → $121 | Initiates | → Buy | |||
05/22/2024 | -9.33% | Citigroup | $128 → $119 | Maintains | Buy | |||
04/22/2024 | 6.67% | Barclays | $141 → $140 | Maintains | Overweight | |||
04/18/2024 | -4.76% | RBC Capital | $128 → $125 | Maintains | Outperform | |||
04/04/2024 | -4.76% | Evercore ISI Group | $120 → $125 | Maintains | Outperform | |||
04/03/2024 | -2.48% | Citigroup | $126 → $128 | Maintains | Buy | |||
02/14/2024 | -2.48% | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/26/2024 | 7.43% | Barclays | $133 → $141 | Maintains | Overweight | |||
01/25/2024 | -2.48% | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/25/2024 | -4% | Citigroup | $123 → $126 | Maintains | Buy | |||
01/25/2024 | -3.24% | Raymond James | $124 → $127 | Maintains | Outperform | |||
01/11/2024 | -2.48% | RBC Capital | $119 → $128 | Maintains | Outperform | |||
01/03/2024 | -5.52% | Raymond James | $110 → $124 | Maintains | Outperform | |||
12/13/2023 | -7.81% | Wells Fargo | $116 → $121 | Maintains | Overweight | |||
12/11/2023 | -6.29% | Citigroup | $122 → $123 | Maintains | Buy | |||
10/19/2023 | 1.33% | Barclays | $132 → $133 | Maintains | Overweight | |||
10/19/2023 | -18.48% | Morgan Stanley | $112 → $107 | Maintains | Equal-Weight | |||
10/19/2023 | -11.62% | Wells Fargo | $136 → $116 | Maintains | Overweight | |||
10/19/2023 | -16.19% | Raymond James | $123 → $110 | Maintains | Outperform | |||
10/02/2023 | -7.05% | Citigroup | $130 → $122 | Maintains | Buy | |||
07/24/2023 | 0.57% | Barclays | $127 → $132 | Maintains | Overweight | |||
07/21/2023 | -14.67% | Morgan Stanley | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | |||
07/21/2023 | -12.38% | Mizuho | $110 → $115 | Assumes | Neutral → Neutral | |||
07/21/2023 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
05/30/2023 | -14.67% | Morgan Stanley | → $112 | Assumes | → Equal-Weight | |||
04/20/2023 | -0.95% | UBS | $117 → $130 | Maintains | Buy | |||
04/20/2023 | -6.29% | Raymond James | $116 → $123 | Maintains | Outperform | |||
04/20/2023 | -3.24% | Barclays | $125 → $127 | Maintains | Overweight | |||
04/20/2023 | -0.95% | Citigroup | $125 → $130 | Maintains | Buy | |||
04/17/2023 | -0.95% | BTIG | $125 → $130 | Maintains | Buy | |||
04/17/2023 | -11.62% | Raymond James | $123 → $116 | Maintains | Outperform | |||
04/10/2023 | 3.62% | Wells Fargo | $140 → $136 | Maintains | Overweight | |||
04/05/2023 | 3.62% | Wells Fargo | $140 → $136 | Maintains | Overweight | |||
03/29/2023 | -10.86% | UBS | → $117 | Assumes | → Buy | |||
01/27/2023 | -4.76% | Barclays | $122 → $125 | Maintains | Overweight | |||
01/26/2023 | -4.76% | BTIG | $120 → $125 | Maintains | Buy | |||
01/26/2023 | -4.76% | Stifel | $110 → $125 | Maintains | Buy | |||
01/26/2023 | -6.29% | Raymond James | $109 → $123 | Maintains | Outperform | |||
01/26/2023 | 0.57% | Bernstein | $125 → $132 | Maintains | Outperform | |||
01/25/2023 | -18.48% | Wolfe Research | $92 → $107 | Maintains | Underperform | |||
01/24/2023 | -16.19% | Mizuho | $105 → $110 | Maintains | Neutral | |||
01/06/2023 | 1.33% | Morgan Stanley | $117 → $133 | Maintains | Overweight | |||
01/04/2023 | -7.05% | Barclays | $114 → $122 | Maintains | Overweight | |||
12/13/2022 | -0.95% | TD Cowen | $130 → $130 | Maintains | Outperform | |||
12/12/2022 | -4.76% | Citigroup | $114 → $125 | Maintains | Buy | |||
10/26/2022 | -20% | Mizuho | → $105 | Initiates | → Neutral | |||
10/21/2022 | -13.14% | Barclays | $118 → $114 | Maintains | Overweight | |||
10/21/2022 | -16.95% | Raymond James | $117 → $109 | Maintains | Outperform | |||
10/20/2022 | -13.14% | Citigroup | $117 → $114 | Maintains | Buy | |||
10/20/2022 | -8.57% | BTIG | $123 → $120 | Maintains | Buy | |||
10/20/2022 | -16.19% | Stifel | $126 → $110 | Maintains | Buy | |||
10/20/2022 | -10.1% | JP Morgan | $125 → $118 | Maintains | Overweight | |||
10/20/2022 | -10.86% | Morgan Stanley | $126 → $117 | Maintains | Overweight | |||
10/20/2022 | -4% | RBC Capital | $132 → $126 | Maintains | Outperform | |||
10/19/2022 | -16.19% | Evercore ISI Group | $114 → $110 | Maintains | Outperform | |||
10/18/2022 | -10.1% | Barclays | → $118 | Initiates | → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Abbott Laboratories (ABT)?
El último precio objetivo de Abbott Laboratories (NYSE:ABT) fue comunicado por Wells Fargo el julio 18, 2025. La firma de analistas fijó un precio objetivo para $142.00 que espera ABT a rise dentro de 12 meses (un posible 8.19% upside). 41 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Abbott Laboratories (ABT)?
La última calificación de analistas para Abbott Laboratories (NYSE:ABT) fue proporcionada por Wells Fargo, y Abbott Laboratories mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Abbott Laboratories (ABT)?
La última revisión al alza de Abbott Laboratories se produjo en julio 18, 2025, cuando Jefferies elevó su precio objetivo a $145. Jefferies anteriormente tenía a hold para Abbott Laboratories.
¿Cuándo fue la última revisión a la baja de Abbott Laboratories (ABT)?
No hay una última revisión a la baja para Abbott Laboratories.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Abbott Laboratories (ABT)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Abbott Laboratories, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Abbott Laboratories se registró el julio 18, 2025, por lo que la próxima calificación estará disponible en torno al julio 18, 2026.
¿Es correcta la calificación de los analistas sobre Abbott Laboratories (ABT)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Abbott Laboratories (ABT) fue un mantuvo con un precio objetivo de $147.00 a $142.00. El precio actual al que cotiza Abbott Laboratories (ABT) es de $131.25, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.